Advertisement
Among the key features of the GelSite(R) polymer are its mucoadhesiveproperties which, in this experimental application, may create a molecularanchor in order to slow or prevent the dispersion of active ingredients awayfrom specific tissue. The technology enables controlled release of injectedsystemic drugs, and its mucoadhesive properties make it a very effectivedelivery vehicle for nasally administered powder-formulated vaccines.
Advertisement
The cardiac tissue application will test the polymer's injectability,gelation kinetics and cyto-compatibility with a variety of cell types.Further tests will access the material's thrombo-embolic potential. If invitro tests are successful, the program will advance to small and large animalmodels, including efficacy evaluations in improving ventricular geometry andglobal heart function in post-myocardial infarction models.
"This evaluation program suggests a broader versatility for the DelSitepolymer technology than was previously envisioned," commented Carlton E.Turner, PhD, CEO of Carrington. "It could be an exciting addition to therange of programs we are advancing in the areas of nasal vaccines andcontrolled release of systemic proteins and peptides."
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,biopharmaceutical and consumer products company currently utilizingnaturally-occurring complex carbohydrates to manufacture and market productsfor mucositis, radiation dermatitis, wound and oral care, as well as tomanufacture and market the nutraceutical raw material Manapol(R) and cosmeticraw material Hydrapol(TM). Carrington also manufactures and markets consumerproducts and manufactures quality products for other companies. Manufacturingoperations comply with cGMP standards. Carrington's DelSite Biotechnologiessubsidiary is developing its proprietary GelSite(R) technology designed toprovide controlled release of peptide and protein-based drugs. Carrington'stechnology is protected by more than 130 patents in 26 countries. Selectproducts carry the CE mark, recognized by more than 20 countries around theworld. For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may beforward-looking. Actual events will be dependent upon a number of factors andrisks including, but not limited to: subsequent changes in plans by theCompany's management; delays or problems in formulation, manufacturing,distribution, production and/or launch of new finished products; changes inthe regulatory process; changes in market trends; and a number of otherfactors and risks described from time to time in the Company's filings withthe Securities & Exchange Commission, including the Form 10-Q, filed May 15,2007.
SOURCE Carrington Laboratories, Inc.
